The FDA announced on Oct. 28, 2025, that Sun Pharmaceutical Industries Inc. is voluntarily recalling Lisdexamfetamine Dimesylate Capsules due to failed dissolution specifications. The recall affects specific lots distributed nationwide.
How to tell if you have it
- Brand: Sun Pharmaceutical
- Product: Lisdexamfetamine Dimesylate Capsules, 60 mg, CII, 100-count bottle
- NDC: 57664-051-88
- Lot codes: AD48711 (Expiry: 4/30/2026), AD50896 (Expiry: 5/31/2026)
- Manufacturer: OHM Laboratories, New Brunswick, NJ
- Distributor: Sun Pharmaceutical Industries, Inc., Cranbury, NJ
The hazard
GovInfoNow's records show the hazard is failed dissolution specifications resulting from out-of-specification results observed during a 12-month long-term stability test at 25°C and 60% relative humidity. The FDA classifies this as a Class II recall.
Context
GovInfoNow's records show Sun Pharmaceutical has 92 other recalls on record since May 21, 2013. Recent brand recalls include a Carbamazepine Tablets recall for black spots on Aug. 3, 2026, and a Perampanel 6mg Tablets recall for label mix-ups on June 17, 2026. Other recent recalls of similar products include Lannett Niacin Extended-release Tablets Recall (May 27, 2026), Golden State NIACIN Extended-Release Tablets Recall (May 29, 2026), and Supernus Trokendi XR 50mg Capsules (Aug. 31, 2026).